Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 09/26 07:11:50 pm
41.7 USD   -1.16%
09/21 ABBOTT LABORATO : Malnutrition Adds $15.5 Billion Annually to Direct..
09/21DJABBOTT LABORATO : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2012 | 10:06pm CEST

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09/21 ABBOTT LABORATORIES : Malnutrition Adds $15.5 Billion Annually to Direct U.S. Me..
09/21 DGAP-NEWS : Abbott Laboratories: Announcement of Intention to Delist
09/21DJABBOTT LABORATORIES : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/21 ABBOTT LABORATORIES : MILITARY $38,669 Federal Contract Awarded to Abbott Labora..
09/20 ABBOTT LABORATORIES : Justification and Approval - Abbott Laboratories Chemical ..
09/20 FUELING PERFORMANCE WITH FAT : EAS® Launches First Ketogenic Meal Replacement Fo..
09/19 ABBOTT LABORATORIES : Nippon Life Insurance Co Lowers stake in Abbott Laboratori..
09/17 JOHNSON & JOHNSON : to buy Abbott's vision unit for $4.3B
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
More news
Sector news : Pharmaceuticals - NEC
05:36pDJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
05:36pDJMYLAN : EpiPen Profit 60% Higher Than Told to Congress
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:05p Amazon's Next Step Toward Global Domination
09/22 JOHNSON & JOHNSON : From Dead Money To Amongst The Best In My Portfolio
09/21 Presenting Apple's First Car
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
09/20 My Top Picks For Q4
Advertisement
Financials ($)
Sales 2016 20 939 M
EBIT 2016 3 925 M
Net income 2016 2 235 M
Debt 2016 2 699 M
Yield 2016 2,46%
P/E ratio 2016 23,62
P/E ratio 2017 18,25
EV / Sales 2016 3,09x
EV / Sales 2017 2,96x
Capitalization 62 019 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 47,8 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-6.06%62 019
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results